Cost-Effectiveness analysis of direct-acting oral anticoagulants for stroke prevention in Thai patients with Non-Valvular atrial fibrillation and a high risk of bleeding
T Rattanachotphanit, C Limwattananon… - …, 2019 - Springer
Objective The objective of this study was to assess the cost effectiveness of direct-acting oral
anticoagulants for stroke prevention in Thai patients with non-valvular atrial fibrillation and a …
anticoagulants for stroke prevention in Thai patients with non-valvular atrial fibrillation and a …
Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control
A Janzic, M Kos - Pharmacoeconomics, 2015 - Springer
Background Vitamin K antagonists, such as warfarin, are standard treatments for stroke
prophylaxis in patients with atrial fibrillation. Patient outcomes depend on quality of warfarin …
prophylaxis in patients with atrial fibrillation. Patient outcomes depend on quality of warfarin …
[HTML][HTML] Cost-effectiveness analysis of oral anticoagulants in stroke prevention among patients with atrial fibrillation in Taiwan
CT Liao, MC Lee, ZC Chen, LJE Ku… - Acta Cardiologica …, 2020 - ncbi.nlm.nih.gov
Background Non-vitamin K oral antagonist anticoagulants (NOACs) have been widely used
in stroke prevention in atrial fibrillation (SPAF). The aim of this study was to compare the …
in stroke prevention in atrial fibrillation (SPAF). The aim of this study was to compare the …
Cost-effectiveness of direct oral anticoagulant vs. warfarin among atrial fibrillation patients with intermediate stroke risk
Background Several studies have shown the cost-effectiveness of direct oral anticoagulants
(DOACs), compared with warfarin, to prevent atrial fibrillation (AF) related complications …
(DOACs), compared with warfarin, to prevent atrial fibrillation (AF) related complications …
Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population
A Amin, M Stokes, D Makenbaeva… - Journal of medical …, 2014 - Taylor & Francis
Objective: Results of randomized clinical trials (RCT) demonstrate that novel oral
anticoagulants (NOAC) are effective therapies for reducing the risk of stroke in non-valvular …
anticoagulants (NOAC) are effective therapies for reducing the risk of stroke in non-valvular …
Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation
AR Harrington, EP Armstrong, PE Nolan Jr, DC Malone - Stroke, 2013 - Am Heart Assoc
Background and Purpose—To estimate the cost-effectiveness of stroke prevention in
patients with nonvalvular atrial fibrillation by using novel oral anticoagulants apixaban 5 mg …
patients with nonvalvular atrial fibrillation by using novel oral anticoagulants apixaban 5 mg …
Medical costs of oral anticoagulants vs warfarin for atrial fibrillation patients with different stroke risks
S Deitelzweig, A Amin, Y Jing, D Makenbaeva… - Cardiology and …, 2013 - Springer
Abstract Introduction The Apixaban for the Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation (ARISTOTLE), Randomized Evaluation of Long-term …
Events in Atrial Fibrillation (ARISTOTLE), Randomized Evaluation of Long-term …
Updating the cost effectiveness of oral anticoagulants for patients with atrial fibrillation based on varying stroke and bleed risk profiles
Background Previous investigations into the cost effectiveness of direct oral anticoagulants
only considered individual stroke risk but not bleed risk even though bleeding is an …
only considered individual stroke risk but not bleed risk even though bleeding is an …
Cost-effectiveness of dabigatran compared with rivaroxaban for prevention of stroke and systemic embolism in patients with atrial fibrillation in China
SJ Dong, B Wu, SD Zhai, YJ Zhang, YB Chu… - Clinical Therapeutics, 2020 - Elsevier
Abstract Purpose In China, dabigatran and rivaroxaban are the only approved non–vitamin
K antagonist oral anticoagulants for the treatment of atrial fibrillation (AF). The goal of this …
K antagonist oral anticoagulants for the treatment of atrial fibrillation (AF). The goal of this …
Cost-effectiveness analysis of non-vitamin K antagonist oral anticoagulants versus warfarin in Thai patients with non-valvular atrial fibrillation
P Dilokthornsakul, S Nathisuwan… - Heart, Lung and …, 2020 - Elsevier
Background Non-vitamin K antagonist oral anticoagulants (NOACs) have been
recommended as preferred options for stroke prevention in patients with atrial fibrillation …
recommended as preferred options for stroke prevention in patients with atrial fibrillation …